



JOINT STATEMENT

08 July 2026

Health regulators warn against the use or dispensing of recalled Semaglutide and Tirzepatide

The South African Pharmacy Council (SAPC), Health Professions Council of South Africa (HPCSA) and the South African Health Products Regulatory Authority (SAHPRA) hereby warn the public, pharmacies and dispensing medical practitioners against any continued use, prescription and/or dispensing of iDEXIS Semaglutide, iDEXIS Tirzepatide, and iDEXIS Semaglutide/Tirzepatide recalled by SAHPRA in June 2026.

The continued use, prescription and dispensing of these products pose a severe risk to patients' safety and/or users. Any healthcare professional found to have dispensed, prescribed or kept stock of the recalled products will face disciplinary action in accordance with applicable legislation, including the Medicines and Related Substances Act, 101 of 1965.

In a Class I, Type A Recall, SAHPRA determined that iDEXIS Semaglutide, iDEXIS Tirzepatide, and iDEXIS Semaglutide/Tirzepatide pose serious safety risk to patients. Thus, any professional found to be prescribing or dispensing them to patients or users will knowingly be endangering the health of the public.

The recall notice, which contains a list of the recalled products, may be accessed at: <https://www.sahpra.org.za/document/idxis-semaglutide-idxis-tirzepatide-idxissemaglutide-tirzepatide/>

ENDS

Issued by:

1. Mr Vincent Tlala, Registrar/CEO, South African Pharmacy Council
2. Dr Boitumelo Semete-Makokotlela, CEO, South African Health Products Authority
3. Dr Karmani S Chetty, Interim Registrar, Health Professions Council of South Africa

For media enquiries, contact:

Priscilla Sekhonyana Health Professions Council of South Africa Cell: 082 801 6685 Email: priscillas@hpcsa.co.za	Glen Bvuma South African Pharmacy Council Cell: 064 501 3767 Email: Glen.Bvuma@sapc.za.org
Rodgers Baloyi South African Health Products Regulatory Authority Cell: 072 432 6397 Email: Rodgers.Baloyi@sahpra.org.za	